LRR-protein RNH1 dampens the inflammasome activation and is associated with COVID-19 severity
Giuseppe Bombaci,Mayuresh Anant Sarangdhar,Nicola Andina,Aubry Tardivel,Eric Chi-Wang Yu,Gillian M Mackie,Matthew Pugh,Vedat Burak Ozan,Yara Banz,Thibaud Spinetti,Cedric Hirzel,Esther Youd,Joerg C Schefold,Graham Taylor,Amiq Gazdhar,Nicolas Bonadies,Anne Angelillo-Scherrer,Pascal Schneider,Kendle M Maslowski,Ramanjaneyulu Allam
DOI: https://doi.org/10.26508/lsa.202101226
IF: 5.781
2022-03-07
Life Science Alliance
Abstract:Inflammasomes are cytosolic innate immune sensors of pathogen infection and cellular damage that induce caspase-1–mediated inflammation upon activation. Although inflammation is protective, uncontrolled excessive inflammation can cause inflammatory diseases and can be detrimental, such as in coronavirus disease (COVID-19). However, the underlying mechanisms that control inflammasome activation are incompletely understood. Here we report that the leucine-rich repeat (LRR) protein ribonuclease inhibitor (RNH1), which shares homology with LRRs of NLRP (nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain containing) proteins, attenuates inflammasome activation. Deletion of RNH1 in macrophages increases interleukin (IL)-1β production and caspase-1 activation in response to inflammasome stimulation. Mechanistically, RNH1 decreases pro-IL-1β expression and induces proteasome-mediated caspase-1 degradation. Corroborating this, mouse models of monosodium urate (MSU)-induced peritonitis and lipopolysaccharide (LPS)-induced endotoxemia, which are dependent on caspase-1, respectively, show increased neutrophil infiltration and lethality in Rnh1 −/− mice compared with wild-type mice. Furthermore, RNH1 protein levels were negatively related with disease severity and inflammation in hospitalized COVID-19 patients. We propose that RNH1 is a new inflammasome regulator with relevance to COVID-19 severity.
biology